Blog

Supriya Lifescience Limited IPO : Important Dates and IPO Information

Supriya Lifesciences Limited initiated its business operations in 1987. The company has been reported as the largest exporter of Salbutamol Sulphate in the previous Financial year. Alongwith this the company has been leading the exports of Ketamine Hydrochloride and Chlorpheniramine Maleate since the last 5 years. One of the major positives for the firm is its business range. It has access to more than 86 Countries to sell its products. The networking of the company is spread across 346 distributors. The company’s manufacturing plant is located in Maharashtra across a land of 23806 sq mtrs. Also the manufacturing capacity for the company is 547 KL/day. Its expansion plans are underway as it has recently occupied more 13000 Sq METRES of land.

IPO DETAILS

Supriya Lifescience Limited IPO is set to launch on 16th Dec., 2021. The subscription timeline extends till 18th Dec, 2021. The size for the IPO is 700.00 Crore Rs.. Shares issued through Fresh Issue are worth Rs. 200.00 Crore Rs. Shares issued through Offer for Sale are worth Rs. 500.00 Crore. The lot size is 50 shares and the price range is 265 Rs. – 274 Rs./ share. The company is going to get listed at both the exchanges NSE and BSE. The face value per share is Rs. 2 and this is a book built issue. The registrar for the company is Link Intime India Private Limited.

TABULAR REPRESENTATION OF IPO DETAILS

IPO OPENING DATE	16th Dec, 2021
CLOSING DATE FOR IPO	18th Dec, 2021
ISSUE TYPE	Book Built Issue
Face Value per share	2 Rs. per share
IPO price band	265 Rs. – 274 Rs.
LOT SIZE	54 shares
MINIMUM ORDER QUANTITY	54 shares
ISSUE SIZE	700.00 Crore Rs.
OFFER FOR SALE	500.00 Crore Rs.
FRESH ISSUE	200.00 Crore Rs.
LISTING AT	NSE, BSE
LISTING DATE	28th Dec, 2021

IMPORTANT DATES

IPO OPENING DATE	16th Dec, 2021
CLOSING DATE FOR IPO	20th Dec, 2021
IPO ALLOTMENT DATE	23rd Dec, 2021
REFUNDS	24th Dec, 2021
DEMAT A/C CREDITED ON	27th Dec, 2021
IPO LISTING DATE	28th Dec, 2021

Supriya Lifescience Limited IPO begins for subscription from 16th Dec, 2021. The IPO subscription would continue till 18th Dec, 2021. The allotment status for the shareholders who applied would come on 23rd Dec, 2021. The refunds for the ones who did not get allotment would be initiated on 24th Dec, 2021. The DEMAT accounts of shareholders would be credited on 27th Dec, 2021. The listing of the company would be accompanied on 28th Dec, 2021.

Lead Managers And Promoters

The promoter of the company is Satish Waman Wagh.

The lead managers are :

ICICI Securities Limited
Axis Capital Limited

The minimum lot size for the company is decided at 54 shares. This holding accounts to 14796 Rs.. The maximum lot size is decided at 702 shares. This amounts to 192348 Rs.. Hence the company’s final holdings would be set as :

	Shares	Amount
Minimum	54 shares	14796 Rs
Maximum	702 shares	192348 Rs

OBJECTIVES FOR THE IPO

The funds can be utilised for General corporate purposes.
Funding requirements of the company.
Paying off the previous borrowings of the company.

COMPANY FINANCIALS

Particulars (in Million Rs.)	2020-21	2019-20	2018-19
ASSETS	4458	3364	2530
REVENUE	3963	3227	2859
NET PROFIT	1238	734	394

The assets of the company are increasing at a very constant pace of almost 800 to 1000 Crore Rs every year. This has also caused a rise in revenue in a smaller proportion of course. But the reason behind this is the development procedure in the newly bought land. Along With this the profits of the firms are increasing rapidly for almost 400 to 500 Crore Rs every year. Thus the company has been performing very well on the fronts of its profitability and revenue. One can go long to invest in this company.

PROS

It is one of the leaders in exporting Salbutamol Sulphate in the previous Financial year. Also for the last 5 years it leads the exports of Ketamine Hydrochloride And Chlorpheniramine Maleate in India.
Its networking channel consists of 346 distributors.
Supriya Lifescience Limited’s products are getting exported to more than 86 countries across the globe.
Its production facility is spread across 23806 Sq Mtrs. Another expansion plan is underway with almost 13000 Sq Mtrs under development for manufacturing activities.

CONS

Company has some borrowings in its balance sheet which will be paid off through the IPO money. This means that the company may be having some liquidity crunch and hence raising IPO money for the same.